<h4>Background</h4>TP53 gain-of-function (GOF) effects lead to cellular responses beyond the capabilities of wild-type TP53 and are known to promote cancer progression, resulting in poorer outcomes in cancer.<h4>Methods</h4>A total of 486 patients diagnosed with non-small cell lung cancer (NSCLC) with baseline DNA sequencing data were enrolled in our study cohort. Here, TP53 is linked to cancer.